Current management of hepatocellular carcinoma

Table 1 Existing series on treatment of hepatocellular cancer: evidence based benefit (NCI classification) and outcome

Treatment	Ref.	Year	Number	5 yr survival
Liver resection (evidence 2A)	Llovet et al[4]	1999	77	51%
	1Fong et al[5]	1999	154	57%
	2Roayaie et al[17]	2012	132	70%
Liver transplantation (evidence 2A)	Mazzaferro et al[18]	1996	444	73.3%
	Llovet et al[4]	1999	87	69%
	Yao et al[19]	2001	70	72.4%
	3Roayaie et al[20]	2002	43	44%
	4Mazzaferro et al[21]	2009	48	75%
Radiofrequency ablation (evidence 2A)	2Sala et al[22]	2004	34	63%
	Vivarelli et al[23]	2004	79	33% (3 yr)
	1Chen et al[24]	2006	71	67.9% (4 yr)
Transarterial chemoembolization (evidence 1A)	DETCH[25]	1995	50	38% (2 yr)
	Llovet et al[26]	2002	40	29% (3 yr)
	Lo et al[27]	2002	40	31% (2 yr)
Radiotherapy (evidence 1A)	5Carr[28]	2004	65	Median 21.3 mo
	6Salem et al[29]	2011	123	Median 20.7 mo
Systemic therapy (evidence 1A)	Llovet et al[30]	2008	299	10.7 mo
	Cheng et al[31]	2009	150	6.5 mo

¹< 5 cm HCC;

²< 3 cm HCC;

³> 5 cm HCC;

⁴Within Milan criteria;

⁵Stage I disease;

⁶Child-Pugh A. DETCH: Group d’Etude et de Traitement du Carcinome He´patocellulaire; HCC: Hepatocellular carcinoma.